CLINICAL QUESTION: What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis? BOTTOM LINE: Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.
Association of immunotherapies with outcomes in relapsing-remitting multiple sclerosis / Tramacere, I.; Del Giovane, C.; Filippini, G.. - In: JAMA. - ISSN 0098-7484. - 315:4(2016), pp. 409-410. [10.1001/jama.2015.18984]
Association of immunotherapies with outcomes in relapsing-remitting multiple sclerosis
Del Giovane C.;Filippini G.
2016
Abstract
CLINICAL QUESTION: What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis? BOTTOM LINE: Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jama.2015.18984.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
138.19 kB
Formato
Adobe PDF
|
138.19 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
